Multi-site study demonstrates efficacy of Draxxin® for SRD
Dec 21, 2021Jennifer Grullon
DISCOVERIES, Issue 11: A multi-site study of pigs with swine respiratory disease (SRD) demonstrates that one dose of Draxxin® (tulathromycin) not only lowers mortality, it can significantly improve...
Fostera® PRRS effective, lasting, safe despite ‘worst-case’ challenges
Dec 08, 2021Jennifer Grullon
DISCOVERIES, Issue 26: It’s well known that modified-live PRRS vaccines help reduce production losses in breeding herds with PRRS. But when the challenge is especially severe, how well and for how...
Early vaccination with Fostera PRRS, long DOI can help stem PRRS losses in growers
Nov 17, 2021Jennifer Grullon
DISCOVERIES, Issue 28: Vaccination as early as 1 day of age with Fostera® PRRS coupled with the vaccine’s long duration of immunity can help pork producers stem the significant economic losses in...
Time for a change? Farms achieve IAV-S-negative pigs after switching to whole-herd vaccination
Oct 06, 2021Jennifer Grullon
DISCOVERIES, Issue 29: IAV-S continues to frustrate US pork producers. From respiratory problems to reproductive challenges, this rapidly changing virus negatively impacts productivity and...
One dose of Draxxin® at weaning for SRD yields multiple benefit
Oct 01, 2021Jennifer Grullon
DISCOVERIES, Issue 13: Pigs from herds with a natural outbreak of swine respiratory disease (SRD) had significantly better outcomes when they received just one injection of Draxxin® (tulathromycin)...
Antimicrobial’s unique attributes explain efficacy against key SRD pathogens
Sep 15, 2021Jennifer Grullon
DISCOVERIES, Issue 12: The efficacy of Draxxin® (tulathromycin) against key swine respiratory disease (SRD) pathogens is largely due to the antimicrobial’s ability to reach and sustain high...
PCV2 vaccine for swine elicits strong cell-mediated immune response
Aug 26, 2021Jennifer Grullon
DISCOVERIES, Issue 9: A porcine circovirus type 2 (PCV2) vaccine from Zoetis produces a robust and lasting cell-mediated immune response.
Pharmacology explains efficacy of Draxxin® for SRD
Aug 04, 2021Jennifer Grullon
DISCOVERIES, Issue 27: Pharmacologic research demonstrating how Draxxin® (tulathromycin) injection behaves in the pig explains why this antimicrobial remains a valuable treatment for swine...
Scientific foundation explains efficacy of Excede® for Swine against SRD pathogens
Jul 14, 2021Jennifer Grullon
DISCOVERIES, Issue 22: A robust body of research explains the efficacy of Excede® for Swine (ceftiofur crystalline free acid) against four of the bacterial pathogens associated with swine...
SRD pathogens remain highly susceptible to key antimicrobials
Jun 24, 2021Jennifer Grullon
DISCOVERIES, Issue 25: Pathogens commonly associated with swine respiratory disease (SRD) remain highly susceptible to key veterinary antimicrobials,
Long duration of antibiotic helps improve clinical outcome after APP challenge
Jun 15, 2021Jennifer Grullon
DISCOVERIES, Issue 10: Pigs treated with one intramuscular dose of Draxxin® (tulathromycin) and then challenged with a virulent strain of APP had significantly reduced mortality and lung lesions...
Field studies demonstrate safety of Fostera® Gold PCV MH vaccine
Jun 09, 2021Jennifer Grullon
DISCOVERIES, Issue 5: Fostera® Gold PCV MH, the inactivated vaccine from Zoetis developed to provide the broadest protection available against porcine circovirus type 2 (PCV2), has been demonstrated...
High prevalence of PCV2 recombinants highlights importance of broad vaccine coverage
May 22, 2021Jennifer Grullon
DISCOVERIES, Issue 21: A recent analysis of porcine circovirus type 2 (PCV2) genetic sequences shows that up to 25% of field strains are recombinants of diverse genotypes, highlighting the importance...
Mix it up: Resuspension times for injectable antibiotics can vary widely
Jan 10, 2021Jennifer Grullon
DISCOVERIES, Issue 24: An analysis of three similar injectable antibiotics used for swine respiratory disease pathogens demonstrates that resuspension times can differ substantially.
Ct values predict PRRS nursery mortality, can guide vaccination decisions
Dec 27, 2020Jennifer Grullon
DISCOVERIES, Issue 18: Obtaining cycle threshold (Ct) values based on processing fluids provides a practical way to identify neonatal pigs at risk for nursery mortality associated with PRRS and can...
Pigs with APP have less mortality, fewer lung lesions after treatment with Excede® for Swine compared to enrofloxacin
Dec 15, 2020Jennifer Grullon
DISCOVERIES, Issue 20: Pigs with swine respiratory disease due to Actinobacillus pleuropneumoniae were treated with Excede® for Swine (ceftiofur crystallinefree acid) or enrofloxacin in a...
Fostera® PRRS protects against diverse PRRS virus field strains
Oct 28, 2020Jennifer Grullon
DISCOVERIES, Issue 19: PRRS has been described as one of the most important swine diseases of the last half-century. An estimated 20% to 25% of herds are still affected, and the syndrome remains the...
Chimera technology offers better path to protection for PCV2
Apr 27, 2020Jennifer Grullon
DISCOVERIES, Issue 6: When PCV2 first became a problem in US swine herds, scientists looked at taking the immunogenic capsid gene from PCV2 and cloning it into the backbone of nonpathogenic PCV type...
Pigs fed BMD® gain more weight faster despite stress in controlled studies
Oct 29, 2019Jennifer Grullon
DISCOVERIES, Issue 15: Grower pigs fed BMD® gained weight faster and had better feed efficiency compared to controls despite exposure to commonly encountered production stressors, studies show.
Aureomycin® granular premix retained higher potency than Terramycin® meal premix in study
Jul 10, 2019Jennifer Grullon
DISCOVERIES, Issue 2: The particle size and distribution of a medicated-feed premix can dramatically affect how much active ingredient ends up in a pig’s digestive tract for disease treatment or...
Two-dose Fostera® Gold PCV MH regimen yields performance advantages
Mar 15, 2019Jennifer Grullon
DISCOVERIES, Issue 16: Pigs in a study that received two doses of Fostera® Gold PCV MH, the new Zoetis vaccine for PCV2 and M. hyo, had numerically fewer reactions, less morbidity, less mortality.
M. hyo treatment with Draxxin® plays important role in SRD management
Mar 02, 2019Jennifer Grullon
DISCOVERIES, Issue 14: Pigs treated for Mycoplasma hyopneumoniae (M. hyo) with a single dose of the injectable antimicrobial Draxxin® (tulathromycin) had significantly better average daily gain and...
Evolution of PCV2 virus, need for broader coverage spurred development of Fostera® Gold PCV MH
Mar 01, 2019Jennifer Grullon
DISCOVERIES, Issue 7: Compelling scientific evidence indicating the need for an updated porcine circovirus type 2 (PCV2) vaccine was the driving force behind the development of Fostera® Gold PCV...
Fostera® Gold PCV MH protects pigs against PCV2a, PCV2b and M. hyo for at least 23 weeks
Mar 01, 2019Jennifer Grullon
DISCOVERIES, Issue 8: Fostera® Gold PCV MH is the only USDA-licensed vaccine that protects pigs against porcine circovirus (PCV) type 2a, PCV2b and M. hyo for at least 23 weeks.
Epitope-comparison study illustrates broad coverage of Fostera Gold® PCV MH against PCV2 viruses
Aug 15, 2018Jennifer Grullon
DISCOVERIES, Issue 4: Swine disease specialists speculated that a PCV2 vaccine containing two genotypes — PCV2a and PCV2b — would significantly improve the coverage provided against PCV2...
Large field trial showed Fostera Gold® PCV MH was effective against prevalent PCV2d genotype
Apr 20, 2018Jennifer Grullon
DISCOVERIES, Issue 3: A large, commercial field trial conducted with Fostera® Gold PCV MH showed it was also effective against PCV2d, the most prevalent genotype of the virus circulating among US...
Pigs vaccinated with Fostera®PCV MH equally protected, weighed nearly 8 pounds more in large comparison trial
Mar 21, 2018Jennifer Grullon
DISCOVERIES, Issue 1: Pigs vaccinated with Fostera® PCV MH were equally protected against porcine circovirus (PCV) type 2d as well as Mycoplasma hyopneumoniae (M. hyo) and weighed 7.78 pounds more...
